Neuralight Inc.

Precision medicine advances with CAR-T and CRISPR therapies, focusing on oncology and rare diseases. Gene and cell therapies are growing, expected to generate over $100bn by 2029. AI and biomarkers are key to future developments, improving trial accrual rates and enabling targeted treatments. Standardization and data are crucial for global accessibility and progress.